🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMASH / Liver DiseaseHas anyone dealt with mash resolution without worsening fibrosis? Page 5

Has anyone dealt with mash resolution without worsening fibrosis?

KevinCompounds Thu, Oct 31, 2024 at 11:40 AM 45 replies 2,606 viewsPage 5 of 9
emma_london
Member
312
1,456
Oct 2024
London, UK
Nov 2, 2024 at 11:22 PM#21
Dr.PulmRoch said:
One practical note: write down what you did and when, before you need it.

This is exactly what I could not find anywhere else. Sending this to two other people who asked me the same thing last week.

18 16sarah_nash92, FitDadDave, RunnerRach and 15 others
Reply Quote Save Share Report
Dr.LeslieOBGYN
Member
567
2,567
May 2024
Dallas, TX
Nov 3, 2024 at 6:19 AM#22

From the other side of the consultation, briefly. The useful move here is to separate what is established from what is widely repeated. Those two sets overlap less than the confident tone of most write-ups suggests, and the second set is where nearly all the disagreement on this board comes from.

Last edited: Nov 3, 2024 at 12:19 PM
19 17FranDenver, Dr.BariatricHTX, LindaRN_retired and 16 others
Reply Quote Save Share Report
TrialNerd_Beth
Senior Member
2,345
11,234
Jan 2024
Bethesda, MD
Nov 3, 2024 at 1:17 PM#23
Dr.LeslieOBGYN said:
The useful move here is to separate what is established from what is widely repeated.

Adding a me-too, because a thread of one person's experience is not much use.

Last edited: Nov 3, 2024 at 5:17 PM
20 18TomTeleRx, DoseLogDan, SleepFixSam and 17 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
matt_MKE
Member
312
1,345
Sep 2024
Milwaukee, WI
Nov 3, 2024 at 8:15 PM#24
Dr.LeslieOBGYN said:
The useful move here is to separate what is established from what is widely repeated.

There is a second half to this that has not been said yet. Take it one variable at a time. Almost every unanswerable question in these threads is unanswerable because three things changed in the same fortnight, and no amount of subsequent argument can untangle them after the fact.

21 19carl_compliance, DanielChem_CHI, marco_milano and 18 others
Reply Quote Save Share Report
PharmacoVig_BOS
Senior Member
1,567
8,901
Feb 2024
Boston, MA
Nov 4, 2024 at 3:13 AM#25

Adding the numbers, since they settle part of this. For anyone reading later: the numbers in this thread are worth checking against a primary source before you act on them, including mine. Half the figures circulating in this community trace back to a secondary summary that dropped a qualifier.

Last edited: Nov 4, 2024 at 6:13 AM
22 20LabKate, kate.chem, DataDave and 19 others
Reply Quote Save Share Report
1345679

Similar Threads

Survodutide MASH Phase 2b — histological improvement data9 replies
Semaglutide and MASH — liver fat reduction quantification13 replies
Non-invasive MASH biomarkers — FibroScan, ELF, FIB-4 on GLP-110 replies
ALT normalization rates on GLP-1 — pooled trial data20 replies
GLP-1 hepatoprotection — direct vs indirect mechanisms16 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register